Home >> Marketplace Directory >> SelectMDx cost-effective in four European countries

SelectMDx cost-effective in four European countries

image_pdfCreate PDF

October 2018—MDxHealth announced that a study validating the cost-effectiveness of Select­MDx for Prostate Cancer has been published in Prostate Cancer and Prostatic Diseases (Govers TM, et al. Epub ahead of print Aug. 20, 2018. doi:10.1038/s41391-018-0076-3).

The study evaluates the potential cost-effectiveness of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in a population of men from France, Germany, Italy, and Spain with elevated prostate specific antigen. The model used in the study compared the current standard of care, in which men undergo initial prostate biopsy in the case of an elevated PSA, with a strategy in which SelectMDx is used to select men for biopsy based on the probability of them harboring the aggressive form of prostate cancer.

CAP TODAY
X